Announcement • Jun 02

Crinetics Pharmaceuticals Presents Six Abstracts Featuring Palsonify And Atumelnant At Endocrine Society Annual Meeting ENDO 2026

Crinetics Pharmaceuticals, Inc. announced that data from six abstracts, including oral presentations featuring PALSONIFY™ (paltusotine) and investigational candidate atumelnant, will be presented at the Endocrine Society’s Annual Meeting, ENDO 2026, June 13-16, 2026, in Chicago, IL. Three abstracts will report data related to PALSONIFY in acromegaly, including an oral presentation featuring long-term (up to two years) efficacy and pooled safety data from the PATHFNDR-1 and PATHFNDR-2 open-label extension (OLE) studies. Additionally, one poster presentation evaluates real-world biochemical control in acromegaly using U.S. claims and laboratory data to identify areas of unmet need for patients and to inform optimization of acromegaly management. Another poster presentation assesses long-term safety and efficacy of PALSONIFY in combination with cabergoline from the ACROBAT Advance trial. Three abstracts from Crinetics’ atumelnant clinical development program will also be presented, including oral presentations of full Phase 2 data in congenital adrenal hyperplasia (CAH) and new interim results from a Phase 1b/2a study in ACTH-dependent Cushing’s syndrome. An additional rapid-fire presentation highlights dose selection data for the Phase 3 trial in CAH. Crinetics will also present a product theater June 15 from 12:30-1:30 CST, titled “Advancing Acromegaly Management: Bridging Clinical Evidence and the Patient Journey with PALSONIFY™ (paltusotine).” Presentation details are shown below. PALSONIFY™ (paltusotine) Presentations: Title (oral presentation): Efficacy and Safety of Once-Daily Oral Paltusotine in Patients with Acromegaly: Up to 2 years in the PATHFNDR-1 and PATHFNDR-2 Open-Label Extension Studies. Authors: Gadelha, M.R. “et. al.” Date/Time: June 14, 1:45 PM – 3:15 PM CT Location: Room W183BC. Title (poster presentation): Long-Term Safety and Efficacy of Once-Daily Oral Paltusotine in Combination With Cabergoline for the Treatment of Patients With Acromegaly. Authors: Gadelha. M.R. “et. al.” Date/Time: June 14; 12:00 PM – 1:30 pm CT Location: ENDO Expo Hall, McCormick Place West. Title (poster presentation): Real-World Biochemical Control in Acromegaly: Insights from US Claims and Laboratory Data. Authors: Wang, S “et. al.” Date/Time: June 15; 12:00 PM – 1:30 pm CT Location: ENDO Expo Hall, McCormick Place West. Atumelnant Presentations: Title (oral presentation): Once Daily Atumelnant (CRN04894) Enables Lowering of Glucocorticoid Doses With Sustained Androgen Reduction in Adults With Congenital Adrenal Hyperplasia. Authors: Srirangalingam, U., “et. al.” Date/Time: June 14, 1:45 PM – 3:15 PM CT Location: Room W184ABC. Title (oral presentation): ‘Block And Replace’ Atumelnant (CRN04894) And Physiologic Hydrocortisone Replacement Rapidly Controls Hypercortisolism In ACTH-dependent Cushing Syndrome. Authors: Elenius, H., “et al” Date/Time: June 14, 3:30 PM – 4:15 PM CT Location: Room W187. Title (rapid-fire and poster presentations): Model-Informed Atumelnant Dose Selection for a Phase 3 Study in Adult Patients With Classic Congenital Adrenal Hyperplasia. Authors: Curd, L., “et. al.” Dates/Times: Rapid Fire: June 14, 1:45 PM - 3:15 PM CT; Poster: June 15, 12:00 PM – 1:30 PM CT Locations: Rapid Fire: Room W184ABC; Poster: ENDO Expo Hall, McCormick Place West. PALSONIFY, a selectively-targeted somatostatin receptor type 2 (SST2) nonpeptide agonist, is the first and only once-daily, oral therapy approved for the treatment of adults with acromegaly who had an inadequate response to surgery and/or for whom surgery is not an option. In Phase 3 studies, once-daily, oral PALSONIFY maintained IGF-1 levels and symptom control in patients with acromegaly who were switched from monthly injectable medications (PATHFNDR-1) and rapidly decreased IGF-1 levels and symptom burden in medically untreated acromegaly patients (PATHFNDR-2). IGF-1 is the primary biomarker endocrinologists use to manage acromegaly patients. Paltusotine is also in Phase 3 clinical development for carcinoid syndrome associated with neuroendocrine tumors (CAREFNDR). Results from a Phase 2 study in carcinoid syndrome demonstrated rapid and sustained reductions in flushing episodes and bowel movement frequency, which are the most common symptoms of carcinoid syndrome. PALSONIFY is approved in the U.S. for the first-line treatment of adults with acromegaly who had an inadequate response to surgery and/or for whom surgery is not an option. It is also approved for use in the EU for the medical treatment of adult patients with acromegaly. Atumelnant, Crinetics’ second investigational compound, is the first once-daily, oral adrenocorticotropic hormone (ACTH) receptor antagonist that acts selectively at the melanocortin type 2 receptor (MC2R) on the adrenal gland. Diseases associated with excess ACTH can have significant impact on physical and mental health. Atumelnant has exhibited strong binding affinity for MC2R in preclinical models and has demonstrated suppression of adrenally derived glucocorticoids and androgens that are under the control of ACTH. Data from a 12-week Phase 2 study demonstrated compelling treatment benefits of atumelnant, evidenced by the rapid, substantial and sustained statistically significant reductions in key CAH disease related biomarkers, including androstenedione and 17-hydroxyprogesterone, in a diverse population. Atumelnant is in development for congenital adrenal hyperplasia and ACTH-dependent Cushing’s syndrome, with the Phase 3 CALM-CAH trial and a Phase 1/2b trial in ADCS currently enrolling patients. PALSONIFY™ (paltusotine) INDICATION: PALSONIFY is a somatostatin receptor agonist indicated for the treatment of adults with acromegaly who had an inadequate response to surgery and/or for whom surgery is not an option. IMPORTANT SAFETY INFORMATION WARNINGS AND PRECAUTIONS: Cholelithiasis and Its Complications: Cholelithiasis, including related complications such as acute cholecystitis and pancreatitis, have been reported. Monitor patients periodically. Discontinue PALSONIFY if complications of cholelithiasis occur and treat appropriately. Hyperglycemia and Hypoglycemia: Hyperglycemia, diabetes mellitus, or hypoglycemia, may occur.

Announcement • Jun 05

+ 1 more update

Crinetics Pharmaceuticals, Inc. Presents New Data At ENDO 2024 That Increases Body of Evidence Positioning Once-Daily, Oral Paltusotine as Potential First-Choice Treatment Option for Acromegaly

Crinetics Pharmaceuticals, Inc. presented findings from its clinical development program evaluating oral, once-daily investigational paltusotine in acromegaly. Data presented included results of the Phase 3 PATHFNDR-2 trial, a new analysis of patient reported outcome (PRO) data from the Phase 3 PATHFNDR-1 trial, and interim long-term efficacy and safety results at 42 months from the open-label ACROBAT Advance extension study. The data were presented at the Endocrine Society’s Annual Meeting (ENDO2024), with findings from PATHFNDR-1 published as a manuscript in The Journal of Clinical Endocrinology & Metabolism. Efficacy and Safety of Once-daily Oral Paltusotine in Medically Untreated Patients with Acromegaly: Results from the Phase 3, Randomized, Placebo-controlled PATHFNDR-2 Study (Abstract #MON-694): PATHFNDR-2 was a randomized, double-blind, placebo-controlled trial with a 24-week treatment period, followed by an optional open-label extension study evaluating paltusotine in 111 participants with active acromegaly (IGF-1 > 1.1 ULN) who were not pharmacologically treated. Results demonstrated: The study met statistical significance (p<0.0001) on the primary endpoint, based on the proportion of participants taking paltusotine (56%) who achieved an insulin-like growth factor 1 (IGF-1) level = 1.0 times the upper limit of normal (xULN) compared to those taking placebo (5%); This represents the second Phase 3 trial showing a significant difference in symptoms favoring paltusotine; Response to paltusotine was rapid, with the majority of the effect in IGF-1 reductions observed between weeks two and four, and sustained throughout treatment; Among those treated with paltusotine, a reduction in IGF-1 levels occurred in 92.6% of patients (n=50/54) by the end of treatment; Paltusotine was generally well-tolerated and no serious adverse events were reported in participants treated with paltusotine. The frequency of participants with at least one treatment emergent adverse event (TEAE) was comparable in the paltusotine treatment arm and placebo arm; and The most commonly reported TEAEs in paltusotine-treated participants included: diarrhea, headache, arthralgia and abdominal pain. The frequency of adverse events considered related to acromegaly was notably lower in paltusotine treated participants compared to placebo treated participants. Use of the Acromegaly Symptom Diary (ASD) in a Phase 3, Placebo-Controlled Study of Once-Daily, Oral Paltusotine in Patients with Acromegaly Switched from Injected Octreotide or Lanreotide (Abstract #MON-156): PATHFNDR-1 was a randomized, double-blind, placebo-controlled trial with a 36-week treatment period, followed by an optional open-label extension study evaluating paltusotine in participants with acromegaly switching from standard-of-care injected depot somatostatin receptor ligands (SRL). The study enrolled participants with acromegaly who were biochemically controlled on octreotide or lanreotide depot monotherapy. The study met the primary endpoint and all three secondary endpoints, as previously announced. Findings clearly demonstrated that once-daily, oral paltusotine maintained biochemical and symptom control in patients with acromegaly switched from SRL. Paltusotine was well tolerated with no severe or serious TEAEs. In a new analysis of PATHFNDR-1 data presented at ENDO2024, Acromegaly Symptom Diary (ASD) scores for patients at screening (and on injected SRL, the current standard of care) were compared to scores while on paltusotine (n=25). The ASD is a novel PRO tool developed in accordance with U.S. Food and Drug Administration (FDA) guidance to assess disease-related symptom burden. Paltusotine was associated with statistically significant reductions in the frequency of breakthrough acromegaly symptom exacerbations for total ASD scores, most bothersome symptom, headache, joint pain, sweating, fatigue, numbness/tingling, sleep difficulty and memory difficulty. Numerical differences favoring paltusotine were seen for the remaining symptoms of leg weakness and swelling. Long-Term Safety and Efficacy of Once-Daily Oral Paltusotine in the Treatment of Patients with Acromegaly: Update from ACROBAT Study (Abstract #MON-695): ACROBAT Advance is an ongoing, six-year, single-arm, open-label extension study of paltusotine in the treatment of patients with acromegaly. This analysis includes interim results as the first enrolled patients approach four years of treatment. Enrolled patients had completed either the ACROBAT Edge or Evolve Phase 2 parent studies. Results demonstrated: Once-daily oral paltusotine treatment was well-tolerated, with stable biochemical and symptom control, comparable to that observed with prior injected SRL; Parent study baseline median IGF-I levels were 1.15× ULN (0.84, 1.46; n=43). In ACROBAT Advance, median IGF-1 levels were 1.14× ULN (0.89, 1.29; n=40), 1.06× ULN (0.87, 1.24; n=35), and 1.08× ULN (0.87, 1.57; n=10) at months 12, 24, and 42, respectively; Important clinical outcomes including acromegaly symptoms, blood pressure, HbA1c, and residual pituitary tumor size were stable over the period of observation; Paltusotine continues to be well-tolerated. The most common adverse events (AEs) (reported at least during the study) were arthralgia (37.2%), headache (30.2%), and fatigue (23.3%). One serious drug-related AE (cholelithiasis) was reported. Of the eight patients who discontinued the study, two were due to AEs (mild or moderate); and Preparation of regulatory filings for paltusotine based on PATHFNDR-1 and PATHFNDR-2 data are currently underway, with a New Drug Application submission to the FDA planned in the second half of 2024.

Pharmaceuticals Industry Growth	5.95%
Revenue growth rate	51.61%
Return on equity	-42.08%
Net Margin	-1,189.88%
Last Earnings Update	30 Jun 2026

Date	Revenue	Earnings	G+A Expenses
30 Jun 26	42	-502	214
31 Mar 26	18	-496	207
31 Dec 25	8	-465	191
30 Sep 25	2	-423	166
30 Jun 25	1	-370	139
31 Mar 25	1	-328	114
31 Dec 24	1	-298	100
30 Sep 24	1	-278	89
30 Jun 24	1	-259	78
31 Mar 24	2	-235	67
31 Dec 23	4	-215	58
30 Sep 23	5	-199	52
30 Jun 23	5	-184	49
31 Mar 23	4	-175	46
31 Dec 22	5	-164	42
30 Sep 22	5	-150	38
30 Jun 22	5	-136	33
31 Mar 22	4	-119	28
31 Dec 21	1	-108	25
30 Sep 21	0	-98	22
30 Jun 21	0	-89	21
31 Mar 21	0	-79	19
31 Dec 20	0	-74	18
30 Sep 20	0	-67	16
30 Jun 20	1	-63	16
31 Mar 20	1	-59	14
31 Dec 19	1	-50	14
30 Sep 19	2	-44	13
30 Jun 19	2	-38	11
31 Mar 19	2	-31	9
31 Dec 18	2	-27	7
30 Sep 18	2	-21	5
30 Jun 18	2	-16	3
31 Mar 18	2	-12	3
31 Dec 17	2	-9	2
31 Dec 16	1	-6	2

Data	Last Updated (UTC time)
Company Analysis	2026/09/03 19:04
End of Day Share Price	2026/08/31 00:00
Earnings	2026/06/30
Annual Earnings	2025/12/31

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

Analyst	Institution
Brian Skorney	Baird
Joshua Schimmer	Cantor Fitzgerald & Co.
David Lebowitz	Citigroup Inc

This company has been acquired

Crinetics Pharmaceuticals Past Earnings Performance

Past criteria checks 0/6

Key information

Recent past performance updates

Second quarter 2026 earnings: EPS and revenues exceed analyst expectations

Crinetics Pharmaceuticals, Inc. to Report Q2, 2026 Results on Aug 04, 2026

First quarter 2026 earnings: EPS in line with analyst expectations despite revenue beat

Crinetics Pharmaceuticals, Inc. to Report Q1, 2026 Results on May 07, 2026

Crinetics Pharmaceuticals, Inc. to Report Q3, 2025 Results on Nov 06, 2025

Second quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind

Recent updates

Vertex Finalizes Crinetics Pharmaceuticals Acquisition and Broadens Executive Leadership Team

Crinetics Pharmaceuticals, Inc. Announces Board, Executive and Board Committee Changes, Effective September 1, 2026

Consensus revenue estimates increase by 29%

Consensus revenue estimates decrease by 14%

Second quarter 2026 earnings: EPS and revenues exceed analyst expectations

Vertex to Acquire Crinetics Pharmaceuticals in $10 Billion Definitive Agreement

CRNX: Vertex Deal Price Will Anchor Shares As Endocrine Data Progresses

CRNX: Takeover Offer And Delayed Rival Entry Will Shape Endocrine Outlook

Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX) agreed to acquire Crinetics Pharmaceuticals, Inc. (NasdaqGS:CRNX) for $9.2 billion.

New major risk - Share price stability

Vertex To Acquire Crinetics For ~$10bn - What Investors Should Know

Vertex Reaches $10 Billion Acquisition Deal for Crinetics Pharmaceuticals Pending Approval

Crinetics Pharmaceuticals, Inc. to Report Q2, 2026 Results on Aug 04, 2026

Atumelnant Hits Phase 2 Goals and PALSONIFY Shows Two-Year Disease Control for Crinetics

CRNX: Delayed Rival Entry Will Support Early Acromegaly Launch Execution

Crinetics Pharmaceuticals (CRNX) Stock Could Be 56.5% Undervalued After ENDO 2026 Data

Crinetics Pharmaceuticals Announces Long-Term Data for Palsonify in Acromegaly Control

Crinetics Pharmaceuticals Presents Full Results from Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia at ENDO 2026

Crinetics Unveils Strong Long-Term Data for PALSONIFY and Pipeline Progress at ENDO 2026

Crinetics Showcases New Data on PALSONIFY and Atumelnant at ENDO 2026 Meeting

Crinetics Pharmaceuticals Presents Six Abstracts Featuring Palsonify And Atumelnant At Endocrine Society Annual Meeting ENDO 2026

Consensus revenue estimates increase by 11%

Industry Analysts Just Upgraded Their Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Revenue Forecasts By 11%

First quarter 2026 earnings: EPS in line with analyst expectations despite revenue beat

Crinetics Pharmaceuticals, Inc., Annual General Meeting, Jun 18, 2026

Crinetics Pharmaceuticals, Inc. Announces European Commission Approval of PALSONIFY for Treatment of Acromegaly in Adults

Chief Development & Operating Officer notifies of intention to sell stock

Crinetics Pharmaceuticals, Inc. to Report Q1, 2026 Results on May 07, 2026

Crinetics Pharmaceuticals Submits Marketing Authorization Application for Palsonify in Brazil

Crinetics Pharmaceuticals, Inc. Announces Resignation of Jeff Knight as Chief Development and Operating Officer, Effective on or About April 10, 2026

Co-Founder & Chief Scientific Officer notifies of intention to sell stock

Crinetics Pharmaceuticals, Inc. Approves Change in Title and Responsibilities for Jeff Knight, from Chief Operating Officer to Chief Development and Operating Officer, Effective January 2, 2026

Crinetics Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $350.139 million.

Consensus revenue estimates increase by 12%

Crinetics Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $350 million.

Crinetics Pharmaceuticals, Inc. Announces Strong PALSONIFY Launch Execution and Positive Results for Concurrent Androstenedione Lowering and Glucocorticoid Dose Reduction in Phase 2 Trial of Atumelnant for Congenital Adrenal Hyperplasia

Founder exercised options to buy US$2.1m worth of stock.

Crinetics Pharmaceuticals, Inc. Announces Resignation of Dana Pizzuti as Chief Medical and Development Officer, Effective from December 31, 2025

Crinetics Pharmaceuticals, Inc. Announces First Patient Dosed in Phase 1/2 Trial Evaluating CRN09682 for the Treatment of Neuroendocrine Tumors and Other Somatostatin Receptor 2-Expressing Tumors

Crinetics Pharmaceuticals, Inc. Announces First Patient Randomized in Pivotal Phase 3 CarefDR Trial Evaluating Paltusotine in Carinoid Syndrome

Crinetics Pharmaceuticals, Inc. to Highlight Neuroendocrine Tumor Research Progress At the 2025 North American Neuroendocrine Tumor Society Annual Meeting

Crinetics Pharmaceuticals, Inc. to Report Q3, 2025 Results on Nov 06, 2025

New minor risk - Share price stability

Independent Director notifies of intention to sell stock

Price target increased by 9.8% to US$76.87

Crinetics Pharmaceuticals, Inc. Announces FDA Approval of Palsonify™? (Paltusotine) for the Treatment of Adults with Acromegaly

Chief Medical & Development Officer notifies of intention to sell stock

Crinetics Pharmaceuticals, Inc. Receives FDA Orphan Drug Designation for Atumelnant in the Treatment of Congenital Adrenal Hyperplasia

Second quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased by 9.0% to US$68.60

Crinetics Pharmaceuticals, Inc. to Present New Long-Term Data Demonstrating Durable Control of Once-Daily, Oral Palsonify™? (Paltusotine) in Acromegaly At Endocrine Society

Crinetics Pharmaceuticals, Inc. to Report Q2, 2025 Results on Aug 07, 2025

Crinetics Pharmaceuticals, Inc. to Showcase the Next Generation of Endocrinology Innovation At Endocrine Society's Annual Meeting, ENDO 2025

Now 21% undervalued after recent price drop

Co-Founder & Chief Scientific Officer notifies of intention to sell stock

Now 20% undervalued after recent price drop

Crinetics Pharmaceuticals, Inc. to Present New Research on Paltusotine, Atumelnant and Unmet Needs in Acromegaly Treatment At the American Association of Clinical Endocrinology Annual Meeting 2025

Consensus revenue estimates fall by 23%

First quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind

Insufficient new directors

Crinetics Pharmaceuticals, Inc., Annual General Meeting, Jun 11, 2025

Crinetics Pharmaceuticals, Inc. to Report Q1, 2025 Results on May 08, 2025

Consensus revenue estimates fall by 20%

Full year 2024 earnings: EPS in line with expectations, revenues disappoint

Crinetics Pharmaceuticals, Inc. Appoints Tobin “Toby” Schilke as Chief Financial Officer, Effective February 28, 2025

Crinetics Pharmaceuticals, Inc. to Report Q4, 2024 Results on Feb 27, 2025

New major risk - Shareholder dilution

Crinetics Announces Positive Topline Results from Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (Cah)